Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075501 · ClinicalTrials.gov registry record · Phase 4
Interactions Between Drug Effects and Environments II
A Phase 4 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 133
- Enrollment target
NCT03075501: Completed Phase 4 study, sponsored by University of Illinois at Chicago.
NCT03075501 is a Phase 4 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 133 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03075501, a Phase 4 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of the study is to determine how associations between drugs and the places where they are experienced influence drug seeking, mood and acute drug responses.
Primary Outcome
The amount of time spent in the two testing rooms is assessed during a 10min exploration test conducted at the orientation session (pre-test) and again at the testing session (post-test). Between the pre- and post-tests, participants complete 4 drug administration sessions; 2 with 20mg MA, 2 with 0mg MA. The Paired Group always receives 20mg MA in the room they spent the least time in at pre-test, and 0mg MA in the other room. The Unpaired Group receives 20mg MA and 0mg MA once in each room. The
Interventions
- DRUG Placebo
- BEHAVIORAL Paired
- DRUG Stimulant or sedative
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2015-11 |
| Est. Completion | 2020-07 |
| Phase | Phase 4 |
What the finished NCT03075501 record still lists
NCT03075501 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03075501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03075501 about?
NCT03075501 is a clinical study titled "Interactions Between Drug Effects and Environments II". The purpose of the study is to determine how associations between drugs and the places where they are experienced influence drug seeking, mood and acute drug responses.
What is the current status of trial NCT03075501?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 133 participants. The study started on 2015-11. Estimated completion is 2020-07.
What interventions are being tested in trial NCT03075501?
The interventions under investigation include: Placebo (DRUG), Paired (BEHAVIORAL), Stimulant or sedative (DRUG).
Who is sponsoring clinical trial NCT03075501?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03075501's enrollment target sits among peer trials
133 610th of 2000 higher than 1,391 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia